Literature DB >> 18522713

T-cell precursor frequencies and long-term outcome following unrelated hematopoietic stem cell transplantation.

B Kircher, D Niederwieser, A Gächter, B Lindner, A Mitterschiffthaler, C Urban, H Greinix, C Peters, K Lätzer, G Gastl, D Nachbaur.   

Abstract

Functional assays measuring alloreactivity of donor cells are desired to detect either cryptic epitopes inducing graft-vs.-host disease (GvHD) after human leukocyte antigen (HLA)-identical hematopoietic stem cell transplantation (HSCT) or permissible HLA mismatches. However, their value in predicting GvHD and survival is still limited. We determined the cytotoxic and helper T-cell precursor (CTLp and HTLp) frequencies by limiting dilution analysis (LDA) in 40 unrelated recipient/donor combinations. The median observation period at the time of this writing was 4.44 years (range from 0.1 to 11.28). Better overall survival was observed in patients with rather low host-specific CTLp and HTLp frequencies, whereas a trend toward high CTLp frequencies was seen in patients with higher incidence of acute GvHD, especially in patients mismatched in HLA-C. CTLp and HTLp frequencies did not correlate with the incidence of chronic GvHD and relapse. In conclusion, we detected a trend toward better overall survival of patient/donor pairs with low CTLp and HTLp frequencies, however, recommend to use LDA as an additional tool for identifying the most suitable donor when more than one fully HLA-matched stem cell donor is available.

Entities:  

Mesh:

Year:  2008        PMID: 18522713     DOI: 10.1111/j.1751-553X.2007.00990.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  1 in total

1.  Association between CTL Precursor Frequency to HLA-C Mismatches and HLA-C Antigen Cell Surface Expression.

Authors:  Moshe Israeli; Dave L Roelen; Mary Carrington; Effie Wang Petersdorf; Frans H J Claas; Geert W Haasnoot; Machteld Oudshoorn
Journal:  Front Immunol       Date:  2014-10-27       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.